Navigation Links
Triple therapy regime puts patients with leukemic form of cutaneous lymphoma in remission
Date:8/15/2011

PHILADELPHIA A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, reports a new study by dermatologists from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

In a retrospective study of 98 patients with advanced Sezary Syndrome treated over a 25 year time span at the Hospital of the University of Pennsylvania patients treated with combination therapy experienced a higher overall response rate compared to previous studies (74.4 percent vs. 63 percent), and a higher complete response rate (30 percent vs. 20 percent). The 5-year overall survival rate was also higher than previously reported (55 percent vs. 30 percent). Researchers concluded that combination immunotherapy is more effective than a single treatment.

"This rare disease, if caught soon enough, may no longer be fatal, thanks to advances in treatment and our understanding of the disease," said Alain Rook, MD, professor of Dermatology and senior author of the study, which appears online in the Archives of Dermatology, a JAMA/Archives journal. "In addition, our improved understanding of prognostic factors will help us tailor treatments for each patient, based on the aggressiveness of their disease, and better predict individual patient outcomes."

Sezary Syndrome is difficult to treat and has had a poor prognosis. In patients with Sezary Syndrome, malignant T-cells proliferate in the blood, while skin on the surface becomes inflamed, scaly and extremely itchy and doesn't respond to typical skin treatments. The lymphoma circulates in the blood, and tumors spread to the lymph nodes and internal organs. Typically, in the past, as few as 30 percent of patients survived 5 years with Sezary Syndrome; on average, patients survived 40 months after diagnosis.

In the Penn study, patients with advanced Sezary Syndrome received multimodality immunotherapy comprised of extracorporeal photopheresis (ECP) and one or more systemic immunostimulatory agents such as interferon alpha, interferon gamma and/or retinoids.

Patients treated at earlier stages of the disease fared better. A complete response, defined as complete clearance of skin, blood and node involvement for at least 4 weeks, was seen in 30 percent of patients (n= 29). Partial response was found in 45 percent of patients (44). The 5-year survival rate for all groups was 55 percent, and was highest in subsets of patients with stage IIIB disease (80 percent), IVA1 (80 percent), IVA2 (76 percent). Overall median survival time was 65 months; for patients with stage IVA1, median survival was 12 years; stage IVA2, 7 years. For patients with stage IIIB, median survival could not yet be calculated because many patients are still living.

Researchers also identified biological factors to help predict how each patient would respond to treatment. They confirmed that patients with a higher circulating tumor burden had a poor response to treatment. Patients with a higher number of antigen-presenting cells had better outcomes, potentially because antigen-presenting cells process the tumor cells killed by ECP treatment.

Based on this research, the efficacy of combination immunotherapy and increased understanding of the disease response to treatments will significantly extend the lives of patients with Sezary Syndrome.


'/>"/>

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-662-6183
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Different subtypes of triple-negative breast cancer respond to different therapies
2. Treatment for Abuse of Anti-Anxiety Drugs Tripled Over 10 Years
3. Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
4. Nationwide utilization of virtual colonoscopy triples, study suggests
5. Philanthropic pledge triples funds for TGen ovarian cancer research
6. Multiple childbirth linked to increased risk of rare, aggressive triple-negative breast cancer
7. Genetic trait could triple odds of whites susceptibility to heavy cocaine abuse
8. Trio of drugs may combat triple negative breast cancer
9. Scientists identify potential new target for treating triple negative breast cancer
10. MRI, CT Scans for ER Patients Triple Over Decade
11. Study finds women with triple negative breast cancer and BRCA mutations have lower risk of recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House ... Blue SKies Buddha, the biography of Rama - Dr. Frederick Lenz. , ... the love of a Buddhist teacher for teaching and helping others. Valentine’s Day ...
(Date:2/12/2016)... ... 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 ... Winston Churchill said, “Those who don’t learn from history are doomed to repeat it.” , ... come knocking this year. But that takes time. , Take a close look at ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker ... Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and ... hydrated before the big event. The invitation-only gifting suite, held this year at the ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, ... the West Penn Burn Center, part of the Allegheny Health Network, has ... bring you the “Space Heaters Need Space” campaign. , “Space Heaters Need ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Vail knee ... Industry Physician Leaders to Know in 2016 . The list consists of physicians establishing, ... physicians to establish this list. , An Ambulatory Surgery Center, also known as ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 The primary goal of this research ... on the usage of liquid biopsy. Key information the ... - Timeframe of liquid biopsy adoption amidst future users ... organization type - Sample inflow to conduct liquid biopsy ... serum, and so on. - Correlation analysis of sample ...
(Date:2/11/2016)... (NasdaqCM: PDEX) today announced financial results for its fiscal 2016 ... its Quarterly Report on Form 10-Q for the second quarter ... today. --> --> Quarter ... --> Net sales for the three months ended December ... from $2.8 million for the three months ended December 31, ...
(Date:2/11/2016)...  Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... of pets, today announced the submission to FDA of ... Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline ... for the control of pyrexia (fever) in horses were ... --> The Chemistry, Manufacturing, and Controls ...
Breaking Medicine Technology: